Opportunity Information: Apply for RFA AI 13 010
Apply for RFA AI 13 010
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Limited Competition Multicenter AIDS Cohort Study Center for the Coordination, Analysis, and Management of the MACS (CAMACS)(UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.279 Drug Abuse and Addiction Research Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Mar 8, 2013 and posted on Mar 8, 2013.
- Applicants must submit their applications by Jul 11, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $17,900,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,400,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following 1. Eligible Applicants Eligible Organizations Only one application from the current CAMACS awardee may be submitted in response to this limited competition Johns Hopkins University (Baltimore, MD) Center for the Coordination, Analysis, and Management of MACS (CAMACS) Foreign Institutions Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Required Registrations Applicant organizations must complete the following registrations as described in the PHS 398 Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations. System for Award Management (SAM) must maintain an active entity registration (formerly CCR registration), to be renewed at least annually. Use the Sam.gov Manage Entity function to manage your entity registrations. See the Grants Registration User Guide at SAM.gov for additional information. eRA Commons All Program Directors/Principal Investigators (PD(s)/PI(s)) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization. All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least 6 weeks prior to the application due date. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the PHS 398 Application Guide.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (RFA-AI-13-010) is a National Institutes of Health (NIH) cooperative agreement to renew and continue the Center for the Coordination, Analysis, and Management of the Multicenter AIDS Cohort Study (CAMACS) under a UM1 mechanism. The core goal is to maintain and strengthen the centralized infrastructure that coordinates a long-running, multicenter research effort focused on men who report sex with men (MSM), with particular emphasis on understanding the long-term natural history of HIV infection as well as the treated history of HIV in the modern therapy era. In practical terms, the award supports the coordination and management backbone that allows multiple research sites and investigators to operate as one cohesive study, ensuring consistency in operations, data standards, specimen handling, and analytic approaches so the cohort can continue producing reliable, comparable findings over time.
A central scientific emphasis of the MACS, as reflected in this announcement, is longitudinal clinical and epidemiologic follow-up, paired with basic research enabled by decades of carefully collected specimens and deeply characterized participant data. The MACS is positioned to answer questions that are difficult to study in shorter projects, such as how HIV infection and its treatment shape health outcomes across many years, what clinical and behavioral factors predict disease progression or complications among HIV-positive MSM, and how patterns of morbidity and aging evolve in this population. Because the cohort has accumulated a uniquely rich archive of data and biospecimens, CAMACS is meant to preserve continuity, protect the value of long-term follow-up, and keep the data pipeline functioning so that ongoing and future analyses remain feasible and scientifically credible.
A notable operational change highlighted in the opportunity is the transition to a rolling cohort design. Rather than remaining a fixed cohort that shrinks over time, the MACS plans to recruit replacement participants as existing members die or are permanently lost to follow-up. The intent is to sustain cohort size, maintain statistical power, and keep the study population relevant for contemporary questions about HIV prevention, treatment outcomes, comorbidities, and aging. This rolling approach also supports continued representativeness of the MSM population affected by HIV over time, which is important as demographics, treatment standards, and the epidemic itself change.
The competition is explicitly limited, reflecting NIH’s view that the continuity of this specific coordinating center is critical. Eligibility is restricted to the current CAMACS awardee institution, with the announcement naming Johns Hopkins University (Baltimore, MD) as the only eligible applicant organization for this limited competition. Foreign institutions and non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible, although foreign components (as defined by NIH policy) are allowed. The FOA also notes standard NIH expectations around registration for applicant organizations and key personnel, including having a DUNS number, maintaining an active SAM registration, and ensuring that Program Directors/Principal Investigators have eRA Commons accounts appropriately affiliated with the applicant organization.
From an administrative and funding standpoint, the opportunity was posted March 8, 2013, with an original and current closing date of July 11, 2013, and an archive date of August 11, 2013. The estimated total funding is listed at $17.9 million, with an award ceiling of $2.4 million. The expected number of awards is listed as four, and the activity is categorized under education and health, with multiple CFDA program numbers referenced, spanning infectious diseases, mental health, drug abuse, and several cancer research areas. The funding instrument is a cooperative agreement, which generally signals that NIH anticipates substantial programmatic involvement in the funded work compared with a standard research project grant, consistent with the complexity and coordination demands of a multicenter cohort enterprise.
Overall, this FOA is about preserving and advancing a major national research resource: a long-established cohort of MSM with extensive longitudinal clinical, behavioral, epidemiologic, and biologic data and specimens. By renewing CAMACS, NIH aims to ensure the MACS continues to generate insights into HIV disease predictors, long-term outcomes in the treatment era, and evolving clinical epidemiology, while modernizing cohort maintenance through a rolling recruitment strategy to sustain the study’s scientific value for years to come.
Frequently Asked Questions (FAQs)
What is the funding opportunity RFA-AI-13-010 about?
RFA-AI-13-010 is an NIH funding opportunity to renew and continue the Center for the Coordination, Analysis, and Management of the Multicenter AIDS Cohort Study (CAMACS). The purpose is to maintain and strengthen the centralized infrastructure that coordinates a long-running, multicenter research effort so multiple sites and investigators can operate as a single cohesive study.
What funding mechanism and instrument are used for this opportunity?
This opportunity uses a UM1 mechanism and is issued as a cooperative agreement. A cooperative agreement indicates substantial NIH programmatic involvement compared with a standard research project grant, which fits the coordination needs of a large multicenter cohort.
What is CAMACS, and what role does it play in the Multicenter AIDS Cohort Study (MACS)?
CAMACS is the coordinating center that provides the operational and analytic backbone for MACS. It supports centralized coordination and management so that study operations, data standards, specimen handling, and analytic approaches remain consistent across sites and over time.
What is the main goal of renewing CAMACS under this FOA?
The main goal is to preserve and advance the centralized infrastructure that keeps MACS functioning as a unified, scientifically credible longitudinal cohort. This includes maintaining continuity of long-term follow-up and protecting the value of the study's accumulated data and biospecimen resources.
What population is the MACS focused on in this announcement?
The MACS research effort described in this announcement focuses on men who report sex with men (MSM), with emphasis on understanding the long-term natural history of HIV infection and the treated history of HIV in the modern therapy era.
What scientific questions is MACS positioned to address according to the FOA?
The cohort is positioned to answer long-term questions that are difficult to study in shorter projects, such as how HIV infection and its treatment shape health outcomes over many years, which clinical and behavioral factors predict disease progression or complications among HIV-positive MSM, and how patterns of morbidity and aging evolve over time.
Why does the FOA emphasize longitudinal follow-up and biospecimens?
The FOA highlights longitudinal clinical and epidemiologic follow-up paired with basic research enabled by decades of carefully collected specimens and deeply characterized participant data. This combination supports credible long-term analyses and makes it possible to study changes in outcomes across extended periods.
What does the FOA mean by maintaining a "centralized infrastructure"?
In this context, centralized infrastructure refers to the systems and processes that keep a multicenter study coordinated and comparable across sites, including consistent operations, standardized data practices, specimen handling procedures, and aligned analytic approaches.
What operational change does the FOA highlight for MACS?
The FOA highlights a transition to a rolling cohort design. Instead of a fixed cohort that shrinks over time, MACS plans to recruit replacement participants as existing members die or are permanently lost to follow-up.
Why is MACS moving to a rolling cohort design?
The rolling cohort approach is intended to sustain cohort size, maintain statistical power, and keep the study population relevant for contemporary questions related to HIV prevention, treatment outcomes, comorbidities, and aging.
How does the rolling cohort approach affect representativeness over time?
According to the FOA, rolling recruitment supports continued representativeness of the MSM population affected by HIV as demographics, treatment standards, and the epidemic change over time.
Who is eligible to apply for this funding opportunity?
Eligibility is restricted to the current CAMACS awardee institution. The FOA identifies Johns Hopkins University (Baltimore, MD) as the only eligible applicant organization for this limited competition.
Is this a limited competition? If so, why?
Yes. The competition is explicitly limited because NIH views continuity of this specific coordinating center as critical to preserving and advancing the MACS as a long-established national research resource.
Are foreign institutions or non-U.S. entities eligible to apply?
No. Foreign institutions and non-U.S. entities are not eligible to apply under this FOA.
Are non-U.S. components of U.S. organizations eligible to apply?
No. The FOA states that non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under this FOA?
Yes. The FOA indicates that foreign components (as defined by NIH policy) are allowed.
What registrations or identifiers are referenced as NIH expectations for applicants and key personnel?
The FOA notes standard NIH expectations, including that applicant organizations have a DUNS number, maintain an active SAM registration, and ensure that Program Directors/Principal Investigators have eRA Commons accounts appropriately affiliated with the applicant organization.
When was this funding opportunity posted, and what are the key dates listed?
The FOA was posted on March 8, 2013. The original and current closing date is July 11, 2013, and the archive date is August 11, 2013.
How much funding is associated with this opportunity?
The estimated total funding is $17.9 million, and the award ceiling is $2.4 million.
How many awards does NIH expect to make under this FOA?
The expected number of awards is four.
What general topic areas or categories are associated with this opportunity?
The activity is categorized under education and health. The FOA also references multiple CFDA program numbers spanning infectious diseases, mental health, drug abuse, and several cancer research areas.
What kinds of work does this award support in practical terms?
In practical terms, the award supports the coordination and management backbone needed for a multicenter cohort study, including ensuring consistency in operations, data standards, specimen handling, and analytic approaches so results remain reliable and comparable over time.
What is the broader purpose of renewing CAMACS for MACS?
The broader purpose is to preserve and advance a major national research resource: a long-established cohort of MSM with extensive longitudinal clinical, behavioral, epidemiologic, and biologic data and specimens, enabling ongoing and future analyses of HIV predictors and long-term outcomes in the modern treatment era.
Browse more opportunities from the same category: Education Health
Next opportunity: Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01)
Previous opportunity: Wildlife Without Borders Critically Endangered Animals Conservation Fund
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 13 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 13 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01) Apply for RFA AI 13 011 Funding Number: RFA AI 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $4,200,000 |
| Limited Competition Scholars Training for the Advancement of Research (STAR) Revision to NINR T32 Training Grants (T32) Apply for RFA NR 13 010 Funding Number: RFA NR 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Apply for PAR 13 146 Funding Number: PAR 13 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 14 003 Funding Number: RFA DA 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 13 157 Funding Number: PA 13 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) Apply for PAR 13 158 Funding Number: PAR 13 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 13 163 Funding Number: PAR 13 163 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01) Apply for PA 13 165 Funding Number: PA 13 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15) Apply for PA 13 166 Funding Number: PA 13 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R21) Apply for PA 13 167 Funding Number: PA 13 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 13 159 Funding Number: PAR 13 159 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 13 169 Funding Number: PAR 13 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Dissertation Research (R36) Apply for PAR 13 182 Funding Number: PAR 13 182 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology (U01) Apply for PAR 13 184 Funding Number: PAR 13 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Image guided Drug Delivery in Cancer (R01) Apply for PAR 13 185 Funding Number: PAR 13 185 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) Apply for RFA MH 14 170 Funding Number: RFA MH 14 170 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21) Apply for RFA MH 14 171 Funding Number: RFA MH 14 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 190 Funding Number: PAR 13 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 13 176 Funding Number: PAR 13 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 189 Funding Number: PAR 13 189 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 13 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.